Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 202

1.

First-line pharmacotherapies for depression - what is the best choice?

Koenig AM, Thase ME.

Pol Arch Med Wewn. 2009 Jul-Aug;119(7-8):478-86. Review.

2.
3.
4.

The implications of pain and physical symptoms in depression.

Jain R.

J Clin Psychiatry. 2009 Jun;70(6):e19.

5.

Pharmacokinetics of duloxetine hydrochloride enteric-coated tablets in healthy Chinese volunteers: a randomized, open-label, single- and multiple-dose study.

Zhao RK, Cheng G, Tang J, Song J, Peng WX.

Clin Ther. 2009 May;31(5):1022-36. doi: 10.1016/j.clinthera.2009.05.005.

PMID:
19539103
6.

Persistence and compliance to antidepressant treatment in patients with depression: a chart review.

Sawada N, Uchida H, Suzuki T, Watanabe K, Kikuchi T, Handa T, Kashima H.

BMC Psychiatry. 2009 Jun 16;9:38. doi: 10.1186/1471-244X-9-38.

7.

Vilazodone: a 5-HT1A receptor agonist/serotonin transporter inhibitor for the treatment of affective disorders.

Dawson LA, Watson JM.

CNS Neurosci Ther. 2009 Summer;15(2):107-17. Review.

PMID:
19499624
8.

Major depressive disorder and hypothalamic-pituitary-adrenal axis activity: results from a large cohort study.

Vreeburg SA, Hoogendijk WJ, van Pelt J, Derijk RH, Verhagen JC, van Dyck R, Smit JH, Zitman FG, Penninx BW.

Arch Gen Psychiatry. 2009 Jun;66(6):617-26. doi: 10.1001/archgenpsychiatry.2009.50.

PMID:
19487626
9.

Escitalopram in the treatment of adolescent depression: a randomized placebo-controlled multisite trial.

Emslie GJ, Ventura D, Korotzer A, Tourkodimitris S.

J Am Acad Child Adolesc Psychiatry. 2009 Jul;48(7):721-9. doi: 10.1097/CHI.0b013e3181a2b304.

PMID:
19465881
10.

Mirtazapine: a review of its use in major depression and other psychiatric disorders.

Croom KF, Perry CM, Plosker GL.

CNS Drugs. 2009;23(5):427-52. doi: 10.2165/00023210-200923050-00006. Review.

PMID:
19453203
11.

An integrated analysis of the safety and tolerability of desvenlafaxine compared with placebo in the treatment of major depressive disorder.

Clayton AH, Kornstein SG, Rosas G, Guico-Pabia C, Tourian KA.

CNS Spectr. 2009 Apr;14(4):183-95.

PMID:
19407730
12.

Depression in the United States household population, 2005-2006.

Pratt LA, Brody DJ.

NCHS Data Brief. 2008 Sep;(7):1-8.

13.

Population pharmacokinetics of orally administered duloxetine in patients: implications for dosing recommendation.

Lobo ED, Quinlan T, O'Brien L, Knadler MP, Heathman M.

Clin Pharmacokinet. 2009;48(3):189-97. doi: 10.2165/00003088-200948030-00005. Erratum in: Clin Pharmacokinet. 2011 Oct 1;50(10):687-8.

PMID:
19385712
14.

Escitalopram versus other antidepressive agents for depression.

Cipriani A, Santilli C, Furukawa TA, Signoretti A, Nakagawa A, McGuire H, Churchill R, Barbui C.

Cochrane Database Syst Rev. 2009 Apr 15;(2):CD006532. doi: 10.1002/14651858.CD006532.pub2. Review.

15.

Is the significant superiority of escitalopram compared with other antidepressants clinically relevant?

Montgomery SA, Möller HJ.

Int Clin Psychopharmacol. 2009 May;24(3):111-8. doi: 10.1097/YIC.0b013e32832a8eb2. Review.

PMID:
19357527
16.

Desvenlafaxine: a new antidepressant or just another one?

Pae CU.

Expert Opin Pharmacother. 2009 Apr;10(5):875-87. doi: 10.1517/14656560902828351 . Review.

PMID:
19351235
17.
18.

Evidence for efficacy and tolerability of vilazodone in the treatment of major depressive disorder: a randomized, double-blind, placebo-controlled trial.

Rickels K, Athanasiou M, Robinson DS, Gibertini M, Whalen H, Reed CR.

J Clin Psychiatry. 2009 Mar;70(3):326-33. Epub 2009 Mar 10.

PMID:
19284933
19.

Beyond the monoaminergic hypothesis: agomelatine, a new antidepressant with an innovative mechanism of action.

Kasper S, Hamon M.

World J Biol Psychiatry. 2009;10(2):117-26. doi: 10.1080/15622970902717024. Review.

PMID:
19255935
20.

Cost effectiveness of venlafaxine compared with generic fluoxetine or generic amitriptyline in major depressive disorder in the UK.

Lenox-Smith A, Greenstreet L, Burslem K, Knight C.

Clin Drug Investig. 2009;29(3):173-84. doi: 10.2165/00044011-200929030-00004. Erratum in: Clin Drug Investig. 2010;30(1):70.

PMID:
19243210

Supplemental Content

Support Center